HOTH - Hoth inks research deal to test HT-006 with UCRI

Hoth Therapeutics (HOTH) announces entering into a Research Agreement with the University of Cincinnati Research Institute ("UCRI") to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan.HT-006 is a novel antibiotic under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia ((HAP)), cystic fibrosis ((CF)), chronic obstructive pulmonary disease ((COPD)) and ventilator-associated pneumonia ((VAP)).The research plan includes critical antimicrobial in vitro characterization studies for HT-006 in alignment with the U.S. FDA program for "antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases."

For further details see:

Hoth inks research deal to test HT-006 with UCRI